AbbVie annual ebitda margin
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
AbbVie EBITDA Margin Growth & History (ABBV)
AbbVie's ebitda margin was 37.96% for fiscal 2025.
View full AbbVie company overviewAbbVie annual ebitda margin history
| Fiscal year | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 37.96% | +6.85 pp |
| 2024 | 2024-12-31 | 31.11% | −8.39 pp |
| 2023 | 2023-12-31 | 39.50% | −6.29 pp |
| 2022 | 2022-12-31 | 45.79% | −1.27 pp |
| 2021 | 2021-12-31 | 47.06% | +8.12 pp |
| 2020 | 2020-12-31 | 38.94% | −6.16 pp |
| 2019 | 2019-12-31 | 45.09% | +20.21 pp |
| 2018 | 2018-12-31 | 24.88% | −14.27 pp |
| 2017 | 2017-12-31 | 39.15% | −1.92 pp |
| 2016 | 2016-12-31 | 41.07% | +4.44 pp |
| 2015 | 2015-12-31 | 36.63% | +15.60 pp |
| 2014 | 2014-12-31 | 21.03% | −13.89 pp |
| 2013 | 2013-12-31 | 34.92% | −2.99 pp |
| 2012 | 2012-12-31 | 37.91% | +9.86 pp |
| 2011 | 2011-12-31 | 28.04% | — |
AbbVie quarterly ebitda margin
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 49.01% | +3.75 pp |
| Q1 2026 | 2026-03-31 | 39.50% | −3.76 pp |
| Q4 2025 | 2025-12-31 | 38.91% | +34.63 pp |
| Q3 2025 | 2025-09-30 | 25.33% | −15.62 pp |
| Q2 2025 | 2025-06-30 | 45.26% | +3.20 pp |
| Q1 2025 | 2025-03-31 | 43.26% | +3.68 pp |
| Q4 2024 | 2024-12-31 | 4.28% | −32.64 pp |
| Q3 2024 | 2024-09-30 | 40.95% | +8.81 pp |
| Q2 2024 | 2024-06-30 | 42.06% | −7.01 pp |
| Q1 2024 | 2024-03-31 | 39.58% | −0.46 pp |
| Q4 2023 | 2023-12-31 | 36.92% | −14.21 pp |
| Q3 2023 | 2023-09-30 | 32.15% | −13.65 pp |
| Q2 2023 | 2023-06-30 | 49.07% | +12.74 pp |
| Q1 2023 | 2023-03-31 | 40.04% | −9.97 pp |
| Q4 2022 | 2022-12-31 | 51.13% | +3.73 pp |
| Q3 2022 | 2022-09-30 | 45.80% | +0.97 pp |
| Q2 2022 | 2022-06-30 | 36.33% | −11.25 pp |
| Q1 2022 | 2022-03-31 | 50.01% | +1.44 pp |
| Q4 2021 | 2021-12-31 | 47.40% | +5.25 pp |
| Q3 2021 | 2021-09-30 | 44.83% | +1.96 pp |
| Q2 2021 | 2021-06-30 | 47.58% | +25.51 pp |
| Q1 2021 | 2021-03-31 | 48.56% | +0.27 pp |
| Q4 2020 | 2020-12-31 | 42.15% | −9.15 pp |
| Q3 2020 | 2020-09-30 | 42.86% | +6.06 pp |
| Q2 2020 | 2020-06-30 | 22.07% | −25.20 pp |
| Q1 2020 | 2020-03-31 | 48.29% | +3.41 pp |
| Q4 2019 | 2019-12-31 | 51.30% | +75.37 pp |
| Q3 2019 | 2019-09-30 | 36.80% | −6.84 pp |
| Q2 2019 | 2019-06-30 | 47.27% | +8.55 pp |
| Q1 2019 | 2019-03-31 | 44.88% | +2.68 pp |
| Q4 2018 | 2018-12-31 | −24.07% | −51.86 pp |
| Q3 2018 | 2018-09-30 | 43.64% | −0.29 pp |
| Q2 2018 | 2018-06-30 | 38.72% | −5.08 pp |
| Q1 2018 | 2018-03-31 | 42.20% | −0.34 pp |
| Q4 2017 | 2017-12-31 | 27.79% | −11.08 pp |
| Q3 2017 | 2017-09-30 | 43.93% | +2.50 pp |
| Q2 2017 | 2017-06-30 | 43.79% | +2.32 pp |
| Q1 2017 | 2017-03-31 | 42.54% | −0.20 pp |
| Q4 2016 | 2016-12-31 | 38.88% | +1.78 pp |
| Q3 2016 | 2016-09-30 | 41.43% | +5.90 pp |
| Q2 2016 | 2016-06-30 | 41.48% | +4.18 pp |
| Q1 2016 | 2016-03-31 | 42.73% | +6.13 pp |
| Q4 2015 | 2015-12-31 | 37.09% | +41.17 pp |
| Q3 2015 | 2015-09-30 | 35.53% | +12.58 pp |
| Q2 2015 | 2015-06-30 | 37.30% | +2.44 pp |
| Q1 2015 | 2015-03-31 | 36.61% | +2.64 pp |
| Q4 2014 | 2014-12-31 | −4.07% | −38.02 pp |
| Q3 2014 | 2014-09-30 | 22.95% | −11.50 pp |
| Q2 2014 | 2014-06-30 | 34.86% | −1.14 pp |
| Q1 2014 | 2014-03-31 | 33.97% | −1.42 pp |
| Q4 2013 | 2013-12-31 | 33.95% | −6.97 pp |
| Q3 2013 | 2013-09-30 | 34.46% | −5.98 pp |
| Q2 2013 | 2013-06-30 | 36.00% | −2.22 pp |
| Q1 2013 | 2013-03-31 | 35.39% | +4.31 pp |
| Q4 2012 | 2012-12-31 | 40.91% | — |
| Q3 2012 | 2012-09-30 | 40.44% | — |
| Q2 2012 | 2012-06-30 | 38.22% | — |
| Q1 2012 | 2012-03-31 | 31.08% | — |
AbbVie ebitda margin trends
Over the last five fiscal years, AbbVie's ebitda margin decreased from 38.94% to 37.96%, a change of −0.98 percentage points. The latest reported quarter, Q2 2026, shows 49.01%.
About the metric
What EBITDA margin means
EBITDA margin measures EBITDA as a percentage of revenue. It can help compare operating profitability over time, but it excludes capital intensity, financing costs, taxes, and other items and is generally unsuitable for financial companies.
Calculation and source
How EBITDA margin is calculated
TickerStat calculates EBITDA margin as EBITDA divided by positive reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review AbbVie source filings ↗Community posts
FDA clears at-home Skyrizi induction for Crohn’s disease
AbbVie ($ABBV) received FDA approval for subcutaneous induction dosing of Skyrizi in adults with moderately to severely active Crohn’s disease. Patients can now begin treatment at home using an on-body injector, extending that delivery opti ...
AbbVie meets pivotal hidradenitis endpoint with lutikizumab
AbbVie ($ABBV) reported that lutikizumab met the main endpoint and all eight ranked secondary endpoints in the Phase 3 INTREPID trial for moderate to severe hidradenitis suppurativa. At week 16, 31.4% of treated patients achieved HiSCR75, c ...
AbbVie’s menstrual-migraine study meets its primary and all ranked secondary goals
AbbVie ($ABBV) reported positive Phase 3 LUNA results for atogepant in menstrual migraine. The study enrolled 468 women and evaluated treatment across three menstrual cycles. Migraine days during the assessed menstrual period fell by 1.20 d ...
